Abstract
The application evaluated here describes the treatment of inflammation and arthritis as two new potential indications for CB1 cannabinoid receptor antagonists. While these derivatives are known for their actions on food intake, energy metabolism and addictions, little is known on their anti-inflammatory properties. Here, the effects of three representative CB1 antagonists, SR141716A, AM251 and a pyrazolo[1,5-a][1,3,5]triazine, are described in rodent in vivo models of inflammation. CB1 receptor blockade decreased the lipopolysaccharide-induced cytokines production, the carrageenan-induced paw inflammation and hyperalgesia, and the signs of arthritis following complete Freund's adjuvant injection. However, no CB1 knockout mice were used to confirm the involvement of the CB1 receptors in the described effects. Thus, additional research is needed to confirm the usefulness of CB1 antagonist in the claimed indications.